Mapping spatiotemporal microproteomics ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Mapping spatiotemporal microproteomics landscape in experimental model of traumatic brain injury unveils a link to parkinson''s disease
Auteur(s) :
Mallah, Khalil [Auteur]
Quanico, Jusal [Auteur]
Raffo-Romero, Antonella [Auteur]
Cardon, Tristan [Auteur]
Aboulouard, Soulaimane [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM]
DEVOS, DAVID [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Kobeissy, Firas [Auteur]
Zibara, Kazem [Auteur]
Salzet, Michel [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM]
FOURNIER, Isabelle [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM]
Quanico, Jusal [Auteur]
Raffo-Romero, Antonella [Auteur]
Cardon, Tristan [Auteur]
Aboulouard, Soulaimane [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM]
DEVOS, DAVID [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Kobeissy, Firas [Auteur]
Zibara, Kazem [Auteur]
Salzet, Michel [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM]
FOURNIER, Isabelle [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM]
Titre de la revue :
Molecular & cellular proteomics . MCP
Nom court de la revue :
Mol. Cell Proteomics
Date de publication :
2019-06-16
ISSN :
1535-9484
Mot(s)-clé(s) en anglais :
Systems biology*
Imaging
Long chain Acylcarnitines
MALDI Mass spectrometry imaging
Spatially resolved Microproteomics
Lipidomics
Spatiotemporal
Parkinson''s disease
Traumatic Brain Injury
Mass Spectrometry
Label-free quantification
Imaging
Long chain Acylcarnitines
MALDI Mass spectrometry imaging
Spatially resolved Microproteomics
Lipidomics
Spatiotemporal
Parkinson''s disease
Traumatic Brain Injury
Mass Spectrometry
Label-free quantification
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Traumatic brain injury (TBI) represents a major health concerns with no clinically-approved FDA drug available for therapeutic intervention. Several genomics and neuroproteomics studies have been employed to decipher the ...
Lire la suite >Traumatic brain injury (TBI) represents a major health concerns with no clinically-approved FDA drug available for therapeutic intervention. Several genomics and neuroproteomics studies have been employed to decipher the underlying pathological mechanisms involved that can serve as potential neurotherapeutic targets and unveil a possible underlying relation of TBI to other secondary neurological disorders. In this work, we present a novel high throughput systems biology approach using a spatially resolved microproteomics platform conducted on different brain regions in an experimental rat model of moderate of controlled cortical injury (CCI) at a temporal pattern postinjury (1 day, 3 days, 7 days, and 10 days). Mapping the spatiotemporal landscape of signature markers in TBI revealed an overexpression of major protein families known to be implicated in Parkinson's disease (PD) such as GPR158, HGMB1, synaptotagmin and glutamate decarboxylase in the ipsilateral substantia nigra. In silicoin vitroin vivosubstantia nigra,Lire moins >
Lire la suite >Traumatic brain injury (TBI) represents a major health concerns with no clinically-approved FDA drug available for therapeutic intervention. Several genomics and neuroproteomics studies have been employed to decipher the underlying pathological mechanisms involved that can serve as potential neurotherapeutic targets and unveil a possible underlying relation of TBI to other secondary neurological disorders. In this work, we present a novel high throughput systems biology approach using a spatially resolved microproteomics platform conducted on different brain regions in an experimental rat model of moderate of controlled cortical injury (CCI) at a temporal pattern postinjury (1 day, 3 days, 7 days, and 10 days). Mapping the spatiotemporal landscape of signature markers in TBI revealed an overexpression of major protein families known to be implicated in Parkinson's disease (PD) such as GPR158, HGMB1, synaptotagmin and glutamate decarboxylase in the ipsilateral substantia nigra. In silicoin vitroin vivosubstantia nigra,Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
CNRS
INSERM
Inserm
Université de Lille
CNRS
INSERM
Inserm
Université de Lille
Date de dépôt :
2019-11-27T13:36:09Z